Research reveals significant associations between environmental microplastic pollution and increased rates of hypertension, diabetes, and stroke across U.S. coastal communities, with pollution levels ranking among top predictors for chronic disease prevalence.
Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.